Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tesaglitazar AstraZeneca.

Tim Davis1

  • 1University of Western Australia, Department of Medicine, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959, Australia. tdavis@cyllene.uwa.edu.au

Idrugs : the Investigational Drugs Journal
|June 12, 2003
PubMed
Summary

Tesaglitazar, a PPAR agonist, is being developed by AstraZeneca for treating diabetes and insulin resistance. Early clinical trials were underway in 2002 for these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Spinal Cord Stimulation Utilization and Implant Status: An Analysis of a Novel, Real-Time, Remote Monitoring Database.

Neuromodulation : journal of the International Neuromodulation Society·2025
Same author

Estimating the burden of vaccine-preventable lower respiratory tract disease in UK primary care: protocol for a prospective surveillance study (AvonCAP GP2).

BJGP open·2024
Same author

Management of metacarpal shaft fractures.

Bone & joint open·2024
Same author

Needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren's contractures of the fingers (Hand-2): study protocol for a randomised controlled trial.

Trials·2024
Same author

Sodium-glucose cotransport-2 inhibitor induced ketoacidosis following coronary artery bypass surgery: implications for management.

Internal medicine journal·2022
Same author

Design of Novel Amphipathic α-Helical Antimicrobial Peptides with No Toxicity as Therapeutics against the Antibiotic-Resistant Gram-Negative Bacterial Pathogen, <i>Acinetobacter Baumannii</i>.

Journal of medicinal chemistry and drug design·2021

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • AstraZeneca is developing tesaglitazar, a novel peroxisome proliferator-activated receptor (PPAR) agonist.
  • Tesaglitazar targets pathways involved in metabolic regulation.

Purpose of the Study:

  • To evaluate tesaglitazar for the potential treatment of type 2 diabetes.
  • To assess the efficacy of tesaglitazar in managing insulin resistance.

Main Methods:

  • Early phase clinical trials were initiated.
  • The study involved assessing the drug's effects in patients with diabetes and insulin resistance.

Main Results:

  • Clinical trials were ongoing as of July 2002.
  • Specific results from the trials are not detailed in this abstract.

Conclusions:

  • Tesaglitazar holds potential as a therapeutic agent for diabetes and insulin resistance.
  • Further clinical development was anticipated based on ongoing trials.

Related Experiment Videos